Selective JAK1 Amide Compound With Reduced JAK2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current JAK inhibitors lack sufficient selectivity for JAK2 and have dose-limiting toxicities due to interference with erythropoietin and thrombopoietin signaling, necessitating the development of a compound with higher selectivity for JAK1 and inhibitory effect on JAK2.
Innovation Solution
An amide compound with a specific chemical structure that selectively inhibits JAK1 activity while maintaining low inhibitory effect on JAK2, represented by Formulas I, IA, and IB, which can be used in pharmaceutical compositions for treating diseases mediated by JAK1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective JAK inhibitors are used to treat inflammations and autoimmune diseases, then therapeutic efficacy is improved, but dose-limiting toxicities occur due to inhibition of JAK2 affecting erythropoietin and thrombopoietin signals
Solution Approach 1:
The invention segments the JAK inhibition activity by designing a compound that selectively targets JAK1 while sparing JAK2. This is achieved through specific molecular structure features that confer JAK1 selectivity, allowing the drug to inhibit only the problematic kinase without affecting erythropoiesis and thrombopoiesis regulated by JAK2
Solution Approach 2:
The compound introduces local quality differences in its molecular structure to achieve selective binding to JAK1 over JAK2. Specific substituents and structural motifs are positioned to create steric and electronic environments that favor JAK1 interaction, thereby achieving selective inhibition at the molecular level
2Object-affected harmful factors
If selective JAK1 inhibitors are developed to avoid JAK2 inhibition, then side effects are reduced, but existing compounds lack high selectivity for JAK2
Solution Approach 1:
The invention changes key molecular parameters including the core heterocyclic structure, substituent types, and positional arrangements to optimize JAK1 selectivity. By systematically varying these parameters, the compound achieves a selectivity ratio exceeding 3-fold for JAK1 over JAK2 in kinase assays
Data Source
AI summary
Provided in the present application are an amide compound, and an isomer, a pharmaceutically acceptable salt, and a pharmaceutical composition thereof, and the use thereof. The amide compound has a structure as represented by formula I. The amide compound of the present application has a significant JAK kinase inhibitory activity, especially a JAKI kinase inhibitory activity, has a higher inhibitory activity on JAK1 kinase than on JAK2 kinase, and can be used as a highly selective JAK1 kinase inhibitor. Therefore, the amide compound of the present application can be used for preparing drugs for treating JAK1 kinase-mediated diseases.